Rare diseases
Investigational molecules
Locations
989 East Hillsdale Boulevard, 94404-2113, United States
Mirum Pharmaceuticals Inc. focuses on clinical research in cholestatic pruritus, including itching associated with primary biliary cholangitis and primary sclerosing cholangitis. The trials examine symptom control in liver-related itch conditions and the role of targeted therapies in reducing pruritus severity.
These studies place emphasis on patient-reported itch outcomes and on treatment options for chronic pruritus linked to cholestatic liver disease.
Mirum Pharmaceuticals Inc. runs clinical trials in conditions such as Hepatitis D, Fragile X syndrome, Alagille syndrome, Progressive familial intrahepatic cholestasis, among others.
Clinical trials run by this sponsor – those enrolling participants first.
A study to evaluate the safety of MRM-3379 in men with Fragile X Syndrome
SpainA study comparing brelovitug to bulevirtide for treating chronic hepatitis delta infection in patients currently receiving bulevirtide
AustriaClinical Trial for Patients with Chronic Hepatitis D: Comparing Brelovitug and Bulevirtide Treatments
AustriaStudy on Long-Term Safety and Effects of Maralixibat for Patients with Alagille Syndrome
BelgiumA Study of Brelovitug Compared to Delayed Treatment in Patients with Chronic Hepatitis Delta Infection
BelgiumStudy on BJT-778 for Patients with Chronic Hepatitis Delta Infection
BulgariaStudy on Volixibat for Treating Itching in Patients with Primary Sclerosing Cholangitis
BelgiumStudy on Volixibat for Treating Itching in Patients with Primary Biliary Cholangitis
BelgiumStudy on Maralixibat Chloride for Treating Itchy Skin in Patients with Cholestatic Pruritus
FranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
